Volume won't come until license news or unknown catalyst. Then get investors and short covering. But you're right volume has sucked past ten weeks. Only buyers it seems are present shareholders. Need new money.
Part of it is that Abattis Bioceuticals Corp. isn't really a sexy name. All/most of us on here have done a great deal of work and know the company. If you didn't - you look at that name and wonder what it is they really do at Abattis. Not saying it's misleading - just saying that it doesn't resonate with most people who don't know what it is or what they do. Abattis sounds somewhat middle eastern and that name could mean a lot of things to a lot of people not familiar with the company. Just saying.